The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981
Open accessAbstract
A retrospective chart review of 98 patients treated with 100 courses of intravenous vancomycin was undertaken to better define its toxicity. Most of the patients carried diagnoses of Staphylococcus aureus or Staphylococcus epidermidis infection. Auditory toxicity was not seen, and fever and rash occurred in only 1 to 3% of the subjects. Phlebitis was noted in 13% of the cases and required discontinuation of therapy in 2%. Therapy was complicated by neutropenia (polymorphonuclear leukocyte count, less than or equal to 1,000 cells per cm3) in 2% of the patients but was rapidly reversible. Nephrotoxicity was uncommon (5%) and reversible in subjects receiving vancomycin alone, even when the therapy was continued. However, 35% of the patients receiving vancomycin with an aminoglycoside developed significant elevations in serum creatinine. Although this high incidence may have been due to the patient population selected or to the aminoglycoside therapy alone, the possibility of additive toxicity between vancomycin and the aminoglycosides should be considered.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Crossley, K., Loesch, D., Landesman, B., Mead, K., Chern, M., & Strate, R. (1979) · Journal of Infectious Diseases · doi:10.1093/infdis/139.3.273 · Cited by 390
Klimek, J. J., Marsik, F. J., Bartlett, R. C., Weir, B., Shea, P., & Quintiliani, R. (1976) · The American Journal of Medicine · doi:10.1016/0002-9343(76)90370-3 · Cited by 236
Crossley, K., Loesch, D. M., Landesman, B., et al. (1979) · Cited by 185
Late prosthetic valve endocarditis
Karchmer, A. W., Dismukes, W. E., Buckley, M. J., & Austen, W. G. (1978) · The American Journal of Medicine · doi:10.1016/0002-9343(78)90046-3 · Cited by 172
Single‐Dose Kinetics of Intravenous Vancomycin
Krogstad, D. J., Moellering, R. C., & GREENRLATT, D. J. (1980) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1980.tb01696.x · Cited by 120
Self-citationToxicology of Vancomycin in Laboratory Animals
Wold, J. S., & Turnipseed, S. A. (1981) · Clinical Infectious Diseases · doi:10.1093/clinids/3.supplement_2.s224 · Cited by 77
The Treatment of Severe Staphylococcal Infections with Vancomycin
WOODLEY, D. W., & HALL, W. H. (1961) · Annals of Internal Medicine · doi:10.7326/0003-4819-55-2-235 · Cited by 66
Effects of vancomycin on renal function in rats
Aronoff, G. R., Sloan, R. S., Dinwiddie, C. B., Glant, M. D., Fineberg, N. S., & Luft, F. C. (1981) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.19.2.306 · Cited by 48
Comparative Clinical Effectiveness and Toxicity of Vancomycin, Ristocetin, and Kanamycin
WAISBREN, B. A. (1960) · Archives of Internal Medicine · doi:10.1001/archinte.1960.03820020019005 · Cited by 41
Cited by
Rybak, M., Lomaestro, B., Rotschafer, J. C., Moellering, R., Craig, W., Billeter, M., Dalovisio, J. R., & Levine, D. P. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp080434 · Cited by 1,795
Self-citationLevine, D. P. (2006) · Clinical Infectious Diseases · doi:10.1086/491709 · Cited by 838
The Pharmacokinetic and Pharmacodynamic Properties of Vancomycin
Rybak, M. J. (2006) · Clinical Infectious Diseases · doi:10.1086/491712 · Cited by 774
Antimicrobial resistance of Staphylococcus aureus: genetic basis
Lyon, B. R., & Skurray, R. A. (1987) · Microbiological Reviews · doi:10.1128/mmbr.51.1.88-134.1987 · Cited by 686
Lodise, T. P., Patel, N., Lomaestro, B. M., Rodvold, K. A., & Drusano, G. L. (2009) · Clinical Infectious Diseases · doi:10.1086/600884 · Cited by 554
Elyasi, S., Khalili, H., Dashti-Khavidaki, S., & Mohammadpour, A. (2012) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-012-1259-9 · Cited by 436
The Nephrotoxicity of Vancomycin
Filippone, E., Kraft, W., & Farber, J. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.726 · Cited by 416
Antibiotic-loaded nanoparticles targeted to the site of infection enhance antibacterial efficacy
Hussain, S., Joo, J., Kang, J., Kim, B., Braun, G. B., She, Z.-G., Kim, D., Mann, A. P., Mölder, T., Teesalu, T., et al. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-017-0187-5 · Cited by 399
Clinical Pharmacokinetics of Vancomycin
Matzke, G. R., Zhanel, G. G., & Guay, D. R. P. (1986) · Clinical Pharmacokinetics · doi:10.2165/00003088-198611040-00001 · Cited by 360
Markowitz, N., Quinn, E. L., & Saravolatz, L. D. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-5-390 · Cited by 343
Jeffres, M. N., Isakow, W., Doherty, J. A., Micek, S. T., & Kollef, M. H. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.06.014 · Cited by 334
Vancomycin: A 50-Year Reassessment
Moellering, R. C. (2006) · Clinical Infectious Diseases · doi:10.1086/491708 · Cited by 275
Self-citationJones, R. N. (2006) · Clinical Infectious Diseases · doi:10.1086/491710 · Cited by 254
Metadata
- Authors
- Farber, B. F., & Moellering, R. C.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 1983-01
- Volume
- 23
- Issue
- 1
- Pages
- 138-141
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2126520713
- Cited by
- 432
- References
- 9
- FWCI
- 15.71
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.